ArticleAmerican journal of audiology2025
Changes in Audiology Visits at an Academic Audiology Practice Following the Food and Drug Administration Over-the-Counter Hearing Aid Ruling.
Article in American journal of audiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeIn 2022, the Food and Drug Administration (FDA) permitted the sale of over-the-counter (OTC) hearing aids nationwide. The impact on audiology practice has not been well characterized. The purpose of this study is to determine if there was a change in the volume of hearing aid evaluations (HAEs) and comprehensive audiologic exams (CAEs) at an academic tertiary care audiology practice following the ruling.
methodData were collected from the billing records of patients ≥ 18 years old. HAE and CAE visits, defined by Current Procedural Terminology and Healthcare Common Procedure Coding System codes, were included. The number of visits was totaled for equal time periods (534 days) before and after October 17, 2022, when OTC hearing aid sales began. Sensitivity analysis (365 days before and after the ruling) accounted for seasonality. Change in visits per day over the entire period was calculated from the slope of the line of best fit.
resultsThe mean (
conclusionsThe FDA OTC hearing aid ruling did not have a meaningful impact on the volume of HAEs and CAEs at an academic audiology practice. We found a small trend toward increased volume. Future studies should investigate visit patterns in other practice models to understand the full impact of the ruling on clinical audiology practice volumes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.